Guggenheim raised the firm’s price target on Apogee Therapeutics to $91 from $44 and keeps a Buy rating on the shares after the company announced results from APG777’s Phase 1 trial that “exceeded all trial objectives.” The Phase 1 profile makes APG777 “the most advanced IL-13 AD asset with Q6M dosing,” says the analyst, who updated the firm’s base and bull case scenarios following the trial report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APGE:
- Apogee Therapeutics Announces Breakthrough Phase 1 Results
- Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
- Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
- Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
- Spyre Therapeutics price target raised to $36 from $27 at Stifel
